Neuroimaging clinics of North America
-
Neuroimaging Clin. N. Am. · Nov 2002
ReviewIntraoperative magnetic resonance imaging and magnetic resonance imaging-guided therapy for brain tumors.
Since their introduction into surgical practice in the mid 1990s, intraoperative MRI systems have evolved into essential, routinely used tools for the surgical treatment of brain tumors in many centers. Clear delineation of the lesion, "under-the-surface" vision, and the possibility of obtaining real-time feedback on the extent of resection and the position of residual tumor tissue (which may change during surgery due to "brain-shift") are the main strengths of this method. High-performance computing has further extended the capabilities of intraoperative MRI systems, opening the way for using multimodal information and 3D anatomical reconstructions, which can be updated in "near real time." MRI sensitivity to thermal changes has also opened the way for innovative, minimally invasive (LASER ablations) as well as noninvasive therapeutic approaches for brain tumors (focused ultrasound). Although we have not used intraoperative MRI in clinical applications sufficiently long to assess long-term outcomes, this method clearly enhances the ability of the neurosurgeon to navigate the surgical field with greater accuracy, to avoid critical anatomic structures with greater efficacy, and to reduce the overall invasiveness of the surgery itself.
-
Dynamic susceptibility contrast imaging has proven to be useful in brain tumor studies, and it provides additional information on tumor characteristics based on the microvascular structure of gliomas. The cerebral blood volume maps can be used to noninvasively grade gliomas, to determine optimal biopsy sites, to separate radiation necrosis from tumor regrowth, and to plan and follow irradiation, chemo- and antiangiogenic therapy. Besides of cerebral blood volume mapping, dynamic susceptibility contrast imaging sets also contain information about the flow and permeability properties of the tumor microvascular system. When combined with the conventional MRI, dynamic susceptibility contrast techniques offer important functional information about the biology of gliomas in a cost-effective way.
-
Neuroimaging Clin. N. Am. · Nov 2002
ReviewInnovations in design and delivery of chemotherapy for brain tumors.
Effectiveness of chemotherapy in patients with brain tumors is hampered by the presence of the blood-brain barrier and drug resistance. In recent years, significant progress has been made in devising innovative methods of design and delivery of chemotherapy for brain tumors. This article has surveyed the issues of blood-brain barrier and drug resistance and explored some of the strategies used to circumvent problems associated with chemotherapy failure in patients with brain tumors.
-
A wide variety of metabolic features of brain tumors can be imaged using PET, including glucose metabolism, blood flow, oxygen consumption, amino acid metabolism, and lipid synthesis. Currently, FDG is the most widely available PET tracer for body imaging and brain imaging. Malignant brain tumors, like many other soft tissue tumors, show increased glucose metabolism, which is reflected on FDG-PET imaging. ⋯ Other tracers, such as 11C-methionine and FCH, also avidly accumulate in brain tumors and have the advantage of low background cortical activity. The relationship between degree of uptake of these agents and tumor grade is not established. These tracers may be useful in specific clinical situations, however, such as tumor localization for treatment planning or evaluation of low-grade tumors.
-
The grave outlook for malignant glioma patients in spite of improvements to current modalities has ushered in new approaches to therapy. Viruses have emerged on the scene and gained attention for their ability to play essentially two roles: first, as vectors for therapeutic gene delivery and second, as engineered infectious agents capable of selectively lysing tumor cells. ⋯ Clinical oncolytic studies, on the other hand, have evaluated a conditionally replicating HSV as an antineoplastic agent. Despite some promise afforded by these trials, further studies are warranted; the investigation of additional viruses to play these roles is inevitable and is now precedented.